Eagle drug for the treatment of malignant hyperthermia ryanodex approved by FDA
-
Last Update: 2014-07-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Ryan ODEX, an injection used by Eagle Pharmaceutical Co., Ltd in the treatment of malignant high fever, was approved by FDA on July 24, 2014 This is the second approval the company received in less than a month Malignant hyperthermia is a potentially fatal genetic disease, usually associated with the use of certain general anesthetics or succinylcholine drugs Eagle pharmaceutical pointed out that ryanodex could be transferred by sea through national or regional wholesalers in August Ryan ODEX is orphan drug, which has a 7-year market monopoly In February 2014, Eagle Pharma received only temporary approval for the treatment of B-cell non Hodgkin's lymphoma due to the patent (ep-3101) of bendamusine hydrochloride injection Original link: http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
